| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-1100 | |
| Phytochemical name or plant extracts | F1012-2 | |
| PMID | 34124254 | |
| Literature evidence | In conclusion, the activity of F1012-2-induced DNA damage in TNBC was found in vivo and in vitro, which might trigger the MAPK pathway through ROS accumulation. | |
| IUPAC name | NA | |
| Phytochemicals’ class or type of plant extracts | Sesquiterpene lactone | |
| Source of phytochemicals or plant Extracts | Eupatorium lindleyanum | |
| Geographical availability | Amur, China North-Central, China South-Central, China Southeast, Hainan, Inner Mongolia, Japan, Khabarovsk, Korea, Manchuria, Myanmar, Nansei-shoto, Philippines, Primorye, Qinghai, Taiwan, Tibet, Vietnam | |
| Plant parts | NA | |
| Other cancers | Breast cancer | |
| Target gene or protein | Cyclin B1, cdc2, p21, p-cdc2. | |
| Gene or Protein evidence | Furthermore, F1012-2 could induce cell cycle arrest at G2/M phase with decreasing expression of cyclin B1, cdc2, and upregulating p21, p-cdc2. | |
| Target pathways | A further study showed that F1012-2-induced DNA damage might be triggered by ROS accumulation and involved activation of MAPK pathway, especially the JNK and ERK signaling pathways. Also, F1012-2 activated Akt and p38 signalling pathways. | |
| IC50 | 3.21± 0.005 μg/ml against MDA-MB-231 1.01± 0.13 μg/ml against MDA-MB-468 | |
| Potency | These results indicate that F1012-2 may be an effective anti-TNBC therapeutic agent. | |
| Cell line/ mice model | MDA-MB-231, MDA-MB-468, MDA-MB-231 xenografts | |
| Additional information | Taken together, our results identified that F1012-2 inhibited cell growth via multiple signalling pathways in vitro and in vivo. These data suggest that F1012-2 may be a potential natural active fraction for the treatment of TNBC. | |
| PubChem ID | NA | |
| Additional PMIDs | 29468753 | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:206259-1 | |
| Safety | In vivo, F1012-2 exhibited a potential antitumour effect in MDA-MB-231 xenografts without apparent toxicity. |